Lilly Ebglyss demonstrates durable disease control in atopic dermatitis
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Evgeniia Gordeeva/iStock via Getty Images
- Most atopic dermatitis patients who received monthly maintenance doses of Eli Lilly’s (NYSE:LLY) Ebglyss (lebrikizumab) saw sustained clear or almost-clear skin for up to three years, according to new data.
- Results from the ADvocate 1 and 2 trials showed that more than 80% of adults and adolescents with moderate-to-severe AD who saw improvement with Ebglyss at week 16 and continued treatment for up to three years experienced sustained skin clearance.
- Other data found that 87% of once monthly and 79% of every two week Ebglyss patients maintained at least 90% improvement in disease extent and severity (EASI-90) at three years.
- The data is being presented at the European Academy of Dermatology and Venereology Congress which runs Sept. 25-28.